98 related articles for article (PubMed ID: 10378701)
1. Myb targeted therapeutics for the treatment of human malignancies.
Gewirtz AM
Oncogene; 1999 May; 18(19):3056-62. PubMed ID: 10378701
[TBL] [Abstract][Full Text] [Related]
2. Oligodeoxynucleotide-based therapeutics for human leukemias.
Gewirtz AM
Stem Cells; 1993 Oct; 11 Suppl 3():96-103. PubMed ID: 7507759
[TBL] [Abstract][Full Text] [Related]
3. Treatment of chronic myelogenous leukemia (CML) with c-myb antisense oligodeoxynucleotides.
Gewirtz AM
Bone Marrow Transplant; 1994; 14 Suppl 3():S57-61. PubMed ID: 7697011
[No Abstract] [Full Text] [Related]
4. Oligonucleotide therapeutics for human leukaemia.
Gewirtz AM
Ciba Found Symp; 1997; 209():169-91; discussion 191-4. PubMed ID: 9383576
[TBL] [Abstract][Full Text] [Related]
5. Oligonucleotide therapeutics: clothing the emperor.
Gewirtz AM
Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
[TBL] [Abstract][Full Text] [Related]
6. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
[TBL] [Abstract][Full Text] [Related]
7. Antisense strategies in the treatment of leukemias.
Calabretta B; Skorski T; Ratajczak MZ; Gewirtz AM
Semin Oncol; 1996 Feb; 23(1):78-87. PubMed ID: 8607034
[TBL] [Abstract][Full Text] [Related]
8. The expression of C-myb in human metastatic melanoma cell lines and specimens.
Walker MJ; Silliman E; Dayton MA; Lang JC
Anticancer Res; 1998; 18(2A):1129-35. PubMed ID: 9615777
[TBL] [Abstract][Full Text] [Related]
9. Oncogene-targeted antisense oligodeoxynucleotides combined with chemotherapy or immunotherapy: a new approach for tumor treatment?
Nieborowska-Skórska M; Nakashima M; Ratajczak M; Steplewski Z; Calabretta B; Skórski T
Folia Histochem Cytobiol; 1994; 32(1):35-40. PubMed ID: 8026602
[TBL] [Abstract][Full Text] [Related]
10. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides.
Ratajczak MZ; Kant JA; Luger SM; Hijiya N; Zhang J; Zon G; Gewirtz AM
Proc Natl Acad Sci U S A; 1992 Dec; 89(24):11823-7. PubMed ID: 1281545
[TBL] [Abstract][Full Text] [Related]
11. RNA targeted therapeutics for hematologic malignancies.
Gewirtz AM
Blood Cells Mol Dis; 2007; 38(2):117-9. PubMed ID: 17215146
[TBL] [Abstract][Full Text] [Related]
12. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic intervention in glomerulonephritis by oligonucleotides.
Kashihara N; Maeshima Y; Makino H
Exp Nephrol; 1997; 5(2):126-31. PubMed ID: 9108994
[No Abstract] [Full Text] [Related]
14. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
[TBL] [Abstract][Full Text] [Related]
15. Perturbing gene expression with oligodeoxynucleotides: research and potential therapeutic applications.
Gewirtz AM
Mt Sinai J Med; 1996; 63(5-6):372-80. PubMed ID: 8898543
[TBL] [Abstract][Full Text] [Related]
16. Antisense strategy in hematological malignancies.
Warzocha K
Cytokines Cell Mol Ther; 1999 Mar; 5(1):15-23. PubMed ID: 10390076
[TBL] [Abstract][Full Text] [Related]
17. Multigene targeting with antisense oligodeoxynucleotides: an exploratory study using primary human leukemia cells.
Opalinska JB; Machalinski B; Ratajczak J; Ratajczak MZ; Gewirtz AM
Clin Cancer Res; 2005 Jul; 11(13):4948-54. PubMed ID: 16000594
[TBL] [Abstract][Full Text] [Related]
18. Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo.
Del Bufalo D; Cucco C; Leonetti C; Citro G; D'Agnano I; Benassi M; Geiser T; Zon G; Calabretta B; Zupi G
Br J Cancer; 1996 Aug; 74(3):387-93. PubMed ID: 8695353
[TBL] [Abstract][Full Text] [Related]
19. Oligonucleotide therapeutics for hematologic disorders.
Agarwal N; Gewirtz AM
Biochim Biophys Acta; 1999 Dec; 1489(1):85-96. PubMed ID: 10806999
[TBL] [Abstract][Full Text] [Related]
20. Antisense therapy in malignant diseases: status quo and quo vadis?
Tamm I
Clin Sci (Lond); 2006 Apr; 110(4):427-42. PubMed ID: 16526947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
